1 The EIC Accelerator Project

The EIC Accelerator program is an integral part of the European Innovation Council (EIC) aimed at supporting innovative small and medium-sized enterprises (SMEs) and startups in Europe, particularly those engaged in deep tech development. This initiative provides funding and resources to help companies scale their operations, accelerate their market entry, and attract further investment, thereby fostering innovation and competitiveness within the European ecosystem.

Funding Structure

The EIC Accelerator program offers a unique funding structure that consists of two primary components: grants and equity.

Purpose and Impact

The primary purpose of the EIC Accelerator is to bolster the European startup ecosystem, particularly in the field of deep technology. By providing substantial financial support, the program aims to bridge the gap between innovative ideas and market-ready products. It also encourages collaboration between companies and private investors, enhancing the likelihood of long-term sustainability and market success.

The EIC Accelerator plays a pivotal role in helping startups scale by providing not only financial resources but also mentorship, networking opportunities, and access to a diverse pool of expertise. This support system enhances the ability of innovative companies to navigate the complex landscape of commercialization and growth, ultimately contributing to the vibrancy of the European economy.

Case Study: Enduro Genetics Aps and the BioScale Project

Enduro Genetics Aps, a Danish company, emerged as a notable winner of the EIC Accelerator program with its project titled BioScale, which stands for Biosensor Activated Biomanufacturing Scale-up. The company successfully submitted its Step 2 proposal on October 5, 2022, and later secured funding through the Step 3 interview process.

Project Overview: BioScale

The BioScale project focuses on developing innovative biosensing technologies to enhance biomanufacturing processes. The initiative aims to optimize production efficiency and product quality by integrating advanced biosensors into manufacturing workflows. This integration allows for real-time monitoring and control over biological processes, which is crucial in industries such as pharmaceuticals, food production, and biofuels.

Technology Background

The core technology behind BioScale involves sophisticated biosensors capable of detecting specific biological markers and conditions within bioreactors. These sensors provide critical data that can be analyzed to make informed decisions about the manufacturing process. By leveraging biosensor technology, Enduro Genetics aims to reduce production times, lower costs, and minimize waste, thereby making biomanufacturing more sustainable and economically viable.

In the context of biomanufacturing, the integration of biosensors facilitates a more responsive and adaptive production environment. Traditional methods often rely on periodic sampling and manual adjustments, which can lead to inefficiencies and delays. In contrast, the BioScale project aims to create a streamlined process where real-time data informs operational decisions, resulting in a more agile and effective biomanufacturing setup.

Conclusion

The EIC Accelerator program serves as a vital catalyst for innovation in the European market, particularly for startups like Enduro Genetics. Through its dual funding structure of grants and equity, the program not only supports the initial stages of development but also encourages sustainable scaling through private investment. The BioScale project exemplifies how cutting-edge technology can drive advancements in biomanufacturing, showcasing the potential for significant impact within the industry and beyond.

2 The Funding Rounds

Enduro Genetics ApS – Financing and Funding Overview Since EIC Accelerator Win

Enduro Genetics ApS, based in Denmark, has experienced significant growth in its financing and investment profile since being selected for EIC Accelerator funding following the October 5, 2022 cut-off.

EIC Accelerator Funding (October 2022)

• Enduro Genetics was officially listed among the companies selected for EIC Accelerator funding after the October 5, 2022 call.
• The EIC Accelerator provides up to €17.5 million per company through a combination of grant and equity investments; however, specific amounts allocated to each winner may vary depending on project needs.

Financing Raised & Total Funding

Since its founding in 2019, Enduro Genetics has raised a total of approximately €18 million as of February 2025. This total includes:

• Pre-seed and seed rounds
• Grants from both the BioInnovation Institute (BII) and the European Innovation Council (EIC)
• A major Series A round closed in early 2025

Breakdown by Rounds

Date	Round	Amount Raised	Investors/Source
Dec 2020	Pre-seed	€470,000	BioInnovation Institute
Apr 2022	Seed	Not publicly disclosed	Senior biotech leaders joined board
Oct/Dec 2022	Grant	Part of €18 million total	European Innovation Council
Dec 17, 2024	Grant	€800,000	GUDP Grant
Feb 3, 2025	Series A	€12 million	Supernova Invest, NOON Ventures, Sandwater

</em>The precise value attributed solely to the EIC grant is not detailed but is included within cumulative figures cited by multiple sources.

Timing & Details of Funding Rounds

Pre-seed Round:
Closed December 2nd, 2020; raised €470k from BII.

Seed Round:
Announced April 7th of 2022; details about exact amount not made public but occurred prior to securing larger institutional grants/funding.

GUDP Grant:
Awarded December 17th of 2024; secured an additional non-dilutive grant (€800k) focused on sustainable food protein production.

Series A Round:
Closed February 3rd of 2025; raised €12m led by Supernova Invest with participation from NOON Ventures (an existing investor doubling down), and Sandwater. This round marked a major milestone aimed at expanding technology deployment and accelerating commercialization across biomanufacturing sectors.

Investor Information

Major investors participating in recent rounds include: - Supernova Invest

• NOON Ventures: Already an early backer during previous rounds
• Sandwater

In addition to these venture investors: - The company received support from public entities such as BII (BioInnovation Institute) via pre-seed capital.

• Significant non-dilutive grants came through Danish innovation programs like GUDP.
• The European Innovation Council provided blended finance support as part of the highly competitive EIC Accelerator scheme.

Investor commentary highlights confidence in both Enduro’s technology platform (“synthetic addiction” or Enduro Sense) and commercial progress with clients across biopharma and industrial biosolutions sectors. Both lead investors noted their enthusiasm about supporting rapid scaling efforts into new verticals following strong validation over prior years.

Company Valuation & Exit Events

No formal disclosure regarding current or post-Series A valuation has been made public as part of available reporting. No exit events—such as IPOs or acquisitions—have occurred to date or been announced since receiving EIC accelerator backing.

However: - As typical for deeptech startups post-Series A with high-profile VC backing—and given continued expansion into large-scale commercial partnerships—future late-stage funding rounds or strategic exits remain possibilities.

No IPO filings nor buyouts have been reported up through May 1st of 2025.

---

Summary Table: Key Financial Milestones Since October 22 Cut-Off

| Year Month Event Amount Participating Investors / Sources | |---------|----------|------------------------|--------------------|--------------------------------------------| |         Dec        │ Pre-seed                        │     €470k                                      │ BioInnovation Institute                                                                     │ │ Apr         │ Seed round │ Not disclosed │ Senior biotech leaders joined board     │ │ Oct/Dec │ EIC Accelerator win │ Part of cumulative funds│ European Innovation Council     │ │ Dec │ GUDP Grant │ €800k │ Danish Green Development & Demonstration Program         | │ Feb │ Series A │ €12m  │ Supernova Invest,
NOON Ventures,
Sandwater |

---

Exit Status

As of May 1st of 2025: No IPOs filed. No buyouts/acquisitions announced.

---

Sources:

• EIC Accelerator winners and statistics October 2022 - Strata.team
• EIC Accelerator October cut-off results PDF
• Raises €12 million to unlock scalable bioproduction – Enduro Genetics
• AgFunderNews: Enduro Genetics raises $12m Series A
• DeepTech startup Enduro Genetics raises Series A
• Enduro News Archive – Press Releases

3 The Press Releases

Enduro Genetics ApS: Post-EIC Accelerator Funding Developments Danish biotech company Enduro Genetics ApS, a winner of the October 2022 EIC Accelerator cut-off, has leveraged its grant to advance its biosensor-driven bioproduction platform. The company’s technology focuses on genetically engineering cells to sustain high productivity in industrial fermentation processes, addressing scalability challenges in biologics manufacturing[^website].

Key Developments Since EIC Funding (2022–2025)

• Series A Funding: In February 2025, Enduro secured €12 million from investors including Supernova Invest and NOON Ventures to expand its platform and commercialize its "Enduro Sense" biosensor technology. Cumulative funding now stands at €18 million, including prior grants[^agfunder][^press].
• Leadership Transition: Christian Munch was appointed CEO in April 2023, with co-founder Peter Rugbjerg transitioning to Chief Scientific Officer[^press].
• GUPD Grant: In December 2024, the company received an €800k GUDP grant for sustainable food protein production using precision fermentation[^press].
• US Partnerships: Collaborations with the Agile BioFoundry (a US Department of Energy consortium) were initiated as early as 2020 and expanded post-EIC funding to demonstrate strain scalability[^website][^press].

Technology Advancements

Enduro’s proprietary "Enduro Sense" biosensors couple essential genes with target product synthesis pathways, ensuring only high-producing cells thrive during fermentation. This approach claims >30% titer improvements and enables extended or continuous production cycles across bacteria, yeast, and fungi[^agfunder][^press].

---

Sources

• EIC Accelerator winners October 2022 - Strata.team
• Enduro Genetics raises $12m Series A - AgFunderNews
• Press releases - Enduro.bio

4 The Technology Advancements

Enduro Genetics ApS Overview

Enduro Genetics ApS, based in Denmark, is a deeptech company that has been transforming the biomanufacturing industry by addressing the challenge of microbial productivity. Founded in 2019, the company was spun out of the Technical University of Denmark and has received significant funding, including support from the BioInnovation Institute and the European Innovation Council (EIC) Accelerator grant.

Advancements Since EIC Accelerator Funding

Since receiving the EIC Accelerator funding on October 5, 2022, Enduro Genetics has made notable advancements in its technology and market presence.

Funding and Investment

Enduro Genetics raised €12 million in a Series A funding round in February 2025, led by Supernova Invest, NOON Ventures, and Sandwater. This investment brings their total funding to approximately €18 million, including previous grants from the BioInnovation Institute and the EIC Accelerator.

Technology Development

The company's patented synthetic addiction technology, known as Enduro Sense, continues to evolve. This technology boosts yields, reduces costs and waste, and enables scalable, sustainable production across various biochemicals, alternative proteins, pharmaceuticals, and more. Enduro Sense can be seamlessly integrated into existing bioprocesses without requiring changes to the cultivation medium, ensuring a straightforward implementation process.

Market Demonstration

Enduro Genetics has demonstrated its technology with several clients, including large biomanufacturing companies. The company offers a flexible partnership model, allowing clients to implement Enduro Sense either on-site or through Enduro's facilities. This approach has enabled Enduro to work with a range of clients across the biopharma and food industries, with plans to deliver several commercial implementations in 2025.

New Features and Technology Improvements

Enduro Sense has been enhanced to maintain high-producing strains in fermentation processes, overcoming strain instability issues and facilitating the production of complex products. The technology does not require antibiotic resistance genes, ensuring safe and compliant handling. Furthermore, Enduro has expanded its focus to include biopharmaceutical expression systems, leveraging its cell reprogramming technology for broader applications.

Patents, Scientific Studies, and Clinical Trials

While specific new patent filings or scientific studies since October 2022 are not detailed in available sources, Enduro's advancements in synthetic addiction technology have been highlighted as a significant innovation in biomanufacturing. Clinical trials or direct medical applications are not reported, as Enduro primarily focuses on bioproduction processes rather than clinical trials.

Conclusion

Enduro Genetics has made substantial progress in developing and commercializing its synthetic biology platform since receiving the EIC Accelerator funding. The company's focus on scalable bioproduction and its ability to integrate technology seamlessly into existing processes have positioned it as a leader in addressing the long-standing challenges of microbial productivity in the biomanufacturing sector.

---

Sources: - Enduro Genetics Raises €12 Million to Unlock the Future of Scalable Bioproduction

• Enduro Genetics | Bioproduction At Scale
• Enduro Genetics ApS
• Enduro Genetics Raises €12 Million to Expand Its Bioproduction Platform
• Enduro Genetics Raises 470,000 EUR Pre-Seed
• Enduro Genetics bags €12M funding
• Enduro Genetics raises $12m to turbocharge biomanufacturing
• DeepTech startup Enduro Genetics raises €12 million to unlock the future of scalable bioproduction
• Enduro Genetics secures €12 M in Series A funding for biomanufacturing

5 The Partnerships and Customers

Enduro Genetics ApS: Partnerships, Customers, and Market Positioning

Enduro Genetics ApS, a Denmark-based synthetic biology startup, has been making significant strides in the biomanufacturing sector since receiving recognition and funding. The company focuses on improving large-scale fermentations using game-changing synthetic biology technology to maximize cell performance.

Partnerships and Customers

Enduro Genetics collaborates with established and upcoming biotech companies to scale microbial production processes. Although specific customer names are not widely disclosed, the company's innovative approach has attracted the attention of leading biomanufacturing companies. Its technology integrates with microbial production hosts, ensuring high productivity and cell health, which is crucial for industrial partners seeking scalable and efficient bioproduction solutions.

New Partners and Customers

While detailed information about new partners or customers is limited, Enduro Genetics continues to expand its network. The company's Series A funding round, led by Supernova Invest, NOON Ventures, and Sandwater, reflects its growing traction and potential for further partnerships.

Nature of New Relationships and Purpose

The relationships formed by Enduro Genetics are centered around enhancing its patented cell programming technology, known as "synthetic addiction," which optimizes microbial cells for high production levels. This technology addresses the long-standing challenge of declining productivity in large-scale industrial processes, making it an attractive solution for partners seeking to improve their bioproduction efficiency.

Market Positioning

Enduro Genetics' advancements position it as a key player in the €400 billion biomanufacturing industry. By offering scalable bioproduction solutions, the company supports the production of various bio-based products, including enzymes, biodegradable materials, alternative proteins, and pharmaceuticals. Its technology helps maintain stable and productive microbial communities, leading to consistent and cost-efficient production.

Impact on Technology Advancements and Scaling

The partnerships and investments in Enduro Genetics are crucial for scaling its technology and expanding its commercial reach. The funding will accelerate the development of its EnduroSense platform, allowing for broader adoption in biopharmaceutical expression systems. This expansion will not only enhance the company's technological capabilities but also increase its market presence, enabling it to tackle more complex bioproduction challenges.

Sources

• Enduro Genetics | Bioproduction At Scale
• Enduro Genetics Raises €12 Million to Unlock the Future of Scalable Bioproduction
• Enduro Genetics Raises €12 Million to Expand Its Bioproduction Platform
• Startups and Spinouts
• Enduro Genetics Raises €12 Million to Expand Its Bioproduction Platform in Denmark

6 The Hiring and Company Growth

Enduro Genetics: Growth and Team Development

Enduro Genetics, a Denmark-based synthetic biology startup, has made significant strides in team growth and development since receiving the EIC Accelerator funding in October 2022. Here are key details about their hiring and team expansion:

Current Headcount and Team Size

As of the latest information, Enduro Genetics employs between 11 and 50 people, but the exact current headcount is not specified.

Hiring Status

While there is no specific mention of current hiring processes, the company's recent funding and strategic appointments suggest an active approach to expanding their team.

Growth and Team Changes

Enduro Genetics has experienced notable growth, particularly with the appointment of Christian Munch as the new CEO, while Peter Rugbjerg continues as Chief Scientific Officer. This change indicates a strategic shift towards commercialization and scaling, leveraging Munch's leadership expertise.

Key Positions Recently Hired

The most significant recent appointment is that of Christian Munch as CEO, who brings leadership experience crucial for the company's commercial expansion.

Impact of New Team Members

New team members, particularly at leadership levels like Christian Munch, play a pivotal role in scaling and growing the company. Their expertise helps in managing expanded operations, securing further funding, and navigating strategic partnerships. This is evident in their successful €12 million Series A funding round, which will be used to enhance their bioproduction platform and accelerate commercialization.

Future Prospects

The addition of key team members and the successful funding round indicate a strong future for Enduro Genetics. With its patented "synthetic addiction" technology, the company aims to revolutionize bioproduction by enhancing microbial productivity, thereby reducing costs and improving efficiency in various industries like pharmaceuticals and biochemicals.

Major Management Changes

The transition of Peter Rugbjerg to Chief Scientific Officer while Christian Munch assumes the role of CEO marks a significant change in management. This shift underscores the company's focus on both scientific innovation and business development.

Sources

• Enduro Genetics | Bioproduction At Scale (www.enduro.bio)
• Enduro Genetics Raises $12m to Turbocharge Biomanufacturing (https://agfundernews.com/enduro-genetics-raises-12m-series-a-to-turbocharge-biomanufacturing)
• Enduro Genetics Raises €12 Million to Expand Its Bioproduction Platform (https://www.biopharminternational.com/view/enduro-genetics-raises-12-million-expand-bioproduction-platform-denmark)
• ENDURO GENETICS: An early focus on patents ensures broad protection (https://www.gipc.dk/en/case-enduro-genetics/)
• Enduro Genetics ApS - Copenhagen, Denmark - Bionity (https://www.bionity.com/en/companies/1045933/enduro-genetics-aps.html)

7 The Media Features and Publications

Overview of Enduro Genetics ApS

Enduro Genetics ApS, a Danish biotechnology company based in Copenhagen, has been making significant strides in the field of synthetic biology, particularly in scalable bioproduction. Since winning the EIC Accelerator funding in October 2022, the company has continued to advance its mission to enhance large-scale fermentations using its patented Enduro Sense technology.

Media Features and Publications

Enduro Genetics has been featured in several publications for its innovative approaches to biomanufacturing:

• Nature Communications: Enduro Genetics' co-founder, Peter Rugbjerg, published research on "Diverse Genetic Error Modes Constrain Biological Production" in 2018.
• PNAS: The company's work on "Synthetic Product Addiction Extends the Productive Lifetime of Engineered Escherichia coli populations" was highlighted in a 2018 publication.
• Life-Sciences-Scandinavia.com: The platform reported on Enduro Genetics' pre-seed funding and other developments in the Danish life sciences sector.

Content from Publications

Publications have emphasized Enduro Genetics' focus on solving microbial productivity challenges, enabling sustainable and scalable production across various industries such as biochemicals, alternative proteins, and pharmaceuticals. The company's technology integrates genetic plug-ins into microbial hosts to ensure high productivity by linking cell health and growth to production.

Podcasts and Interviews

There is no publicly available information about specific podcasts or interviews featuring the team of Enduro Genetics ApS.

Conference and Fair Visits, Presentations, or Participations

While there is no detailed information on recent conference participations or presentations by Enduro Genetics, the company's involvement in collaborative projects, such as working with the US Agile BioFoundry, highlights its engagement with international biotechnology communities.

Involvement in Events

Enduro Genetics has been involved in various funding initiatives and collaborative projects. For example, it secured a GUDP grant to advance precision continuous fermentation for sustainable food protein production and raised €12 million in Series A funding to expand its bioproduction platform.

Sources

• Enduro Genetics ApS | PRESS
• Enduro Genetics | Bioproduction At Scale
• Enduro Genetics closes first funding round and strengthens team to broadly enable large-scale biological production
• Enduro Genetics Raises €12 Million to Expand Its Bioproduction Platform
• Enduro Genetics ApS - Copenhagen, Denmark
• News > Denmark